Michael G Kelly

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
    Michael G Kelly
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology and Pathology, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Gynecol Oncol 98:353-9. 2005
  2. ncbi request reprint Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
    June Y Hou
    Yale University School of Medicine, USA
    Gynecol Oncol 105:211-7. 2007
  3. doi request reprint Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers
    Michael G Kelly
    Division of Gynecology Oncology, University of Colorado School of Medicine, Denver, CO, USA
    Int J Gynecol Cancer 21:633-9. 2011
  4. ncbi request reprint Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies
    Jessica N McAlpine
    Yale University School of Medicine, Department of Obstetrics, Gynecology and Reproductive Medicine, Division of Gynecologic Oncology, 333 Cedar Street, New Haven, CT 06510, USA
    Gynecol Oncol 103:288-92. 2006
  5. ncbi request reprint Malignant transformation of myomas: myth or reality?
    Peter E Schwartz
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Obstet Gynecol Clin North Am 33:183-98, xii. 2006
  6. ncbi request reprint TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
    Michael G Kelly
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cancer Res 66:3859-68. 2006

Detail Information

Publications6

  1. ncbi request reprint Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
    Michael G Kelly
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology and Pathology, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Gynecol Oncol 98:353-9. 2005
    ..The purpose of this study was to evaluate the efficacy of adjuvant platinum-based chemotherapy and vaginal cuff radiation in a large cohort of surgical stage I UPSC patients...
  2. ncbi request reprint Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
    June Y Hou
    Yale University School of Medicine, USA
    Gynecol Oncol 105:211-7. 2007
    ....
  3. doi request reprint Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers
    Michael G Kelly
    Division of Gynecology Oncology, University of Colorado School of Medicine, Denver, CO, USA
    Int J Gynecol Cancer 21:633-9. 2011
    ..In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant ovarian cancers...
  4. ncbi request reprint Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies
    Jessica N McAlpine
    Yale University School of Medicine, Department of Obstetrics, Gynecology and Reproductive Medicine, Division of Gynecologic Oncology, 333 Cedar Street, New Haven, CT 06510, USA
    Gynecol Oncol 103:288-92. 2006
    ..We describe the "atypical platinum reactions" (APH) of 14 patients and our experience with skin testing and desensitization...
  5. ncbi request reprint Malignant transformation of myomas: myth or reality?
    Peter E Schwartz
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Obstet Gynecol Clin North Am 33:183-98, xii. 2006
    ..Nevertheless, this article addresses major issues that a clinician might face in the evaluation of a smooth muscle tumor of the uterus that clinically may be malignant...
  6. ncbi request reprint TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer
    Michael G Kelly
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Cancer Res 66:3859-68. 2006
    ..In addition, we provide new evidence that links TLR-4 signaling, inflammation, and chemoresistance in ovarian cancer cells...